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SCIENTIFIC EDITORIAL
New/actual  cardiac  biomarkers  in  patients  with
suspected  acute  myocardial  infarction:  Are  we  close
to  identifying  the  ‘Holy  Grail’?
Biomarqueurs  cardiaques  récents  chez  les  patients  suspects  d’infarctus  du
myocarde  :  pouvons-nous  espérer  atteindre  le  Saint  Graal  ?
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The  daily  challenge  for  physicians  in  emergency  departments  (ED)  relies  on  a  combina-
tion  of  risk  stratiﬁcation  and  diagnostic  procedures,  thereby  allowing  optimal  triage  of
patients.  Biomarkers  are  key  in  the  triage  of  patients  with  suspected  acute  myocardial
infarction  (AMI);  ﬁnding  the  best  interpretation  provided  by  a  biomarker  (or  a  combination
of  biomarkers)  is  therefore  crucial.  If  poorly  sensitive,  information  provided  by  a  biomarker
will  lead  to  a  hazardous  discharge  and  therefore  a  high  risk  of  adverse  events.  Conversely,
poor  speciﬁcity  will  lead  to  the  admission  of  a  large  number  of  low-risk  patients,  further
increasing  the  use  of  healthcare  resources.
Over  the  past  decade,  cardiac  biomarkers  (other  than  troponins)  have  been  the  topic  of
intense  medical  research.  If  the  cardiospeciﬁcity  of  cardiac  troponins  (cTn)  has  never  been
questioned,  the  main  objective  of  exploring  new  candidates  is  to  ﬁnd  a  way  of  increasingInfarctus  du  myocarde
sensitivity  for  the  diagnosis  of  AMI.  Indeed,  many  articles  reported  the  possible  high  merit
of  some  new  candidates,  which  provided  additive  information  corresponding  to  speciﬁc
pathophysiological  pathways  including,  for  example,  inﬂammation,  endogenous  stress  and
plaque  rupture  in  acute  myocardial  infarction  (AMI)  [1—3]. . .  Very  recently,  some  research
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roups  have  focused  on  the  recently  developed  sensitive
ssays  for  cTn,  which  can  detect  very  low  circulating  cTn
oncentrations  and  allow  precise  determination  of  the  99th
ercentile  in  the  general  population.  While  there  was  grow-
ng  literature  about  their  increased  sensitivity  to  detect
MI,  [4—6]  there  was  also  growing  scepticism  among  clini-
ians  as  to  whether  these  sensitive  assays  are  associated
ith  a  clinically  signiﬁcant  improvement  in  comparison  with
onventional  (i.e.  non-sensitive)  cTn  assays.  Yet,  the  key
uestions  about  new  assays  may  be,  for  example:  is  the  prin-
ipal  objective  to  determine  the  risk  proﬁle  of  a  population
r  to  assess  individual  risk?  What  is  the  overall  improve-
ent  of  increased  sensitivity  offered  by  these  new  assays
fter  integration  of  the  associated  cost:  decreased  speci-
city?  Are  these  sensitive  assays  clinically  helpful?  That  is,
ill  they  help  clinicians  improve  patient  outcomes,  and  are
ther  early  markers  of  myocardial  injury  redundant?  If  the
nswer  is  yes,  how  should  clinicians  incorporate  these  assays
nto  clinical  practice?  If  the  answer  is  no,  how  do  we  reach
he  ‘‘Holy  Grail’’?
It  is  easy  to  answer  to  the  ﬁrst  question:  clinicians  will
e  largely  interested  in  individual  risk  stratiﬁcation.  There
re  a  ‘‘myriad’’  of  existing  risk  stratiﬁcations  tools  and
ndexes;  one  should  keep  in  mind  that  the  most  powerful
ndexes  are  based  on  a  combination  of  data,  including  clini-
al,  electrocardiographic  and  biological  measurements.  As  a
onsequence,  the  demonstration  that  one  of  the  most  pow-
rful  tools  used  for  risk  stratiﬁcation  —  the  GRACE  risk  score
 is  neither  affected  nor  improved  by  the  incorporation  by
ew  biomarkers,  such  as  natriuretic  peptides  or  sensitive
Tn  assays  might  be  expected  [7].  In  addition,  we  should  be
ware  that  we  always  analyse  the  risk  information  offered
y  these  scores  in  the  context  of  the  results  of  clinical  tri-
ls,  which  unfortunately  predominantly  randomize  low-risk
atients.
The  possible  beneﬁt  offered  by  a  new  test  is  hard  to
etermine,  as  most  of  the  studies  are  retrospective  or
bservational.  However,  existing  data  clearly  suggest  that
ensitive  cTn  assays  offer  better  and  earlier  identiﬁcation
f  patients  with  AMI,  and  the  balance  of  a  true  positive  in
atients  newly  identiﬁed  with  an  AMI  through  these  sensi-
ive  assays  is  not  counterbalanced  by  over-identiﬁcation  of
atients  without  an  AMI  but  with  elevation  of  cTn  [4,6,8].
he  study  by  Mills  et  al.  published  in  the  Journal  of  the
merican  Medical  Association  in  2011  is  also  very  informa-
ive  [9].  The  authors  studied  1038  patients  with  suspected
MI  during  the  validation  period,  when  decisions  were  based
n  contemporary  cTn  assays,  and  1054  patients  during  an
mplementation  phase  when  decisions  were  based  on  the
esults  of  sensitive  cTn  assays.  The  authors  demonstrated
hat  reducing  the  decision  threshold  (using  a  sensitive
ssay)  was  associated  with  a  marked  reduction  in  recurrent
MI/mortality  (from  39%  at  1  year,  to  7%),  when  physicians
ere  informed  of  the  assay  results  and  thus  were  able  to
odify  management  strategies  accordingly  [9].
How  then  to  incorporate  these  new  assays  into  standard
are?  And  will  the  increased  rate  of  patients  with  cTn
levation  complicate  triage  procedures  in  emergency
epartments?  On  the  one  hand,  there  is  clear  evidence  that
ortality  and  AMI  rates  increase  progressively  with  cTn  con-
entrations  above  the  99th  percentile.  On  the  other  hand,
he  unequivocal  answer  to  ‘‘cTn  positivity’’  should  no  longerC.  Meune  et  al.
e  encouraged,  as  we  will  capture  many  patients  who  will
ave  little  to  gain  and  perhaps  even  more  to  lose  from
nvasive  procedures.  To  illustrate  this,  we  recently  studied
atients  who  presented  to  the  emergency  departments  with
cute  chest  pain  and  were  discharged  after  serial  measure-
ents  of  contemporary  cTn,  but  who  had  mild  and  stable
levation  of  high-sensitivity  cTnT  [10]. We  conﬁrmed  the
ncrease  in  intermediate-  and  long-term  risk  of  death/AMI  in
hese  patients  with  mildly  elevated  cTn  but  showed  that  that
he  rate  of  30-day  events  was  very  low;  overall  our  data  sug-
est  that  these  patients  are  in  need  of  further  investigations
nd  treatments,  but  not  necessarily  immediate  hospitaliza-
ion  [10].
Although  the  development  of  sensitive  cTn  assays  should
e  considered  as  a  major  improvement  in  the  management
f  patients  suspected  of  AMI  and  should  be  recommended  for
aily  practice,  there  is  still  a  long  way  to  go  before  capturing
he  Holy  Grail.  In  fact,  controversies  still  exist  about  the
est  use  of  these  assays;  for  example,  the  consideration  of
n  absolute  or  relative  change  in  cTn  concentrations,  the
xact  timing  of  serial  measurement  [11], and  the  algorithm
o  use  in  speciﬁc  populations  (e.g.  patients  with  a  history  of
ardiac  disease  or  elderly  patients).  Furthermore,  the  initial
eneﬁt  of  some  biomarkers  in  addition  to  conventional  cTn
ssays  needs  be  re-addressed  and  compared  with  sensitive
Tn  assays;  one  can  speculate  that  some,  but  not  all,  will
ail  [12—14]. The  use  of  reclassiﬁcation  indexes  should  be
ncouraged  in  these  future  studies  [15].
To  conclude,  the  development  of  sensitive  assays  of
Tn  measurement  is  highly  clinically  signiﬁcant,  but  only
f  clinicians  interpret  the  results  appropriately  [16]. The
ut-off  value  should  be  set  at  the  level  of  99th  percentile
alue;  minor  elevations  of  cTn  have  broad  possible  origins,
ncluding  acute  (possibly  myocardial  ischaemia)  and  chronic
ardiac  disorders.  Importantly,  they  have  prognostic  signiﬁ-
ance.  More  highly  elevated  cTn  concentrations  more  often
orrespond  to  AMI,  but  alternative  cardiac  diagnoses  do
xist.
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